FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016397716> ?p ?o ?g. }

• W2016397716 abstract "CRM1 (Xpo1) is the major export factor for proteins from the nucleus to the cytoplasm, including tumor suppressors (TSPs) and other modulators of proliferative responses such as p53, FOXO, c-Abl, pRB and IκB. Leptomycin B (LMB), a non-drug like natural product is a potent inhibitor of CRM1-mediated nucleocytoplasmic transport. LMB and related analogs trap TSPs and other proteins in the nucleus, forcing neoplastic cells into apoptosis while normal cells undergo reversible cell cycle arrest. However, LMB has limited efficacy in vivo due to its severe gastrointestinal toxicity. Here, we describe our lead compound KPT-0127 a novel small molecule, water soluble, drug-like, selective, irreversible CRM1 antagonist. Like LMB, KPT-0127 forms a covalent bond with Cys528 in the CRM1 cargo-binding pocket, abrogating most, but not all, export functions of CRM1. KPT-0127 exerts a potent (EC50 300-400nM) and prolonged inhibition of CRM1- mediated HIV-1 Rev, forkhead (FOXO), and p53 nuclear export in a variety of normal and transformed cell lines. In cytotoxicity assays, KPT-0127 showed high potency in most hematologic cancer cell lines (EC50 5-10µM). Studies in the HCT-116 colon cancer cell line suggested that KPT-0127 dose dependently increases the nuclear levels of p53 and appears to induce cell cycle arrest at both the G1/S and G2/M checkpoints, prior to inducing apoptosis. In normal peripheral blood mononuclear cells (PBMCs) and in Hut78 leukemia cells, KPT-0127 potently increased the nuclear levels of IκB. However, KPT-0127 induced cell death of Hut78 cells with no effect on normal PBMCs. In drug combination studies, KPT-0127 showed additive or synergistic cytotoxicity activity with either 5-FU, carboplatin, or doxorubicin. Mechanism of action studies demonstrated that the Cys528 residue in the cargo-binding pocket of CRM1 is essential for the inhibitory effect of KPT-0127. Mutagenesis of Cys528 to a Ser completely abrogated KPT-0127 inhibition. KPT-0128, the transisomer of KPT-0127, shows little effect on both HIV-Rev nuclear export and in cytotoxicity assays (EC50s > 10μM), supporting the specificity of KPT-0127 for CRM1. Moreover, the selectivity of KTP-0127 was demonstrated across a panel of 37 proteins including several cysteine proteases. In single dose mouse toxicology studies, KPT-0127 was generally well tolerated (oral or SC) up to 560 mg/kg, and no deaths were observed. SC dosing daily for 5 days up to 100mg/kg (the highest dose tested) showed no behavioral, clinical chemistry, or hematogical effects in mice; Pharmacokinetics of KPT-0127 is adequate and in vivo efficacy studies are currently being performed; results will be presented. All together, these data demonstrate that KPT-0127 represents a novel, tumor selective, and well-tolerated irreversible Crm1 inhibitor which may be suitable for clinical development both as a single agent and in combination with standard therapies. Citation Information: Clin Cancer Res 2010;16(14 Suppl):A19." @default.
• W2016397716 created "2016-06-24" @default.
• W2016397716 creator A5013530081 @default.
• W2016397716 creator A5027303286 @default.
• W2016397716 creator A5037541103 @default.
• W2016397716 creator A5051352882 @default.
• W2016397716 creator A5054346929 @default.
• W2016397716 creator A5071420169 @default.
• W2016397716 creator A5080351994 @default.
• W2016397716 creator A5080610604 @default.
• W2016397716 creator A5087233806 @default.
• W2016397716 creator A5089084793 @default.
• W2016397716 date "2010-07-15" @default.
• W2016397716 modified "2023-09-27" @default.
• W2016397716 title "Abstract A19: KPT0127, a novel, potent, and selective inhibitor of Crm1-mediated nuclear export shows selective cytotoxicity for neoplastic over normal cells and is well tolerated in animals" @default.
• W2016397716 doi "https://doi.org/10.1158/1078-0432.tcmusa10-a19" @default.
• W2016397716 hasPublicationYear "2010" @default.
• W2016397716 type Work @default.
• W2016397716 sameAs 2016397716 @default.
• W2016397716 citedByCount "1" @default.
• W2016397716 countsByYear W20163977162014 @default.
• W2016397716 crossrefType "proceedings-article" @default.
• W2016397716 hasAuthorship W2016397716A5013530081 @default.
• W2016397716 hasAuthorship W2016397716A5027303286 @default.
• W2016397716 hasAuthorship W2016397716A5037541103 @default.
• W2016397716 hasAuthorship W2016397716A5051352882 @default.
• W2016397716 hasAuthorship W2016397716A5054346929 @default.
• W2016397716 hasAuthorship W2016397716A5071420169 @default.
• W2016397716 hasAuthorship W2016397716A5080351994 @default.
• W2016397716 hasAuthorship W2016397716A5080610604 @default.
• W2016397716 hasAuthorship W2016397716A5087233806 @default.
• W2016397716 hasAuthorship W2016397716A5089084793 @default.
• W2016397716 hasConcept C105696609 @default.
• W2016397716 hasConcept C109316439 @default.
• W2016397716 hasConcept C153911025 @default.
• W2016397716 hasConcept C190062978 @default.
• W2016397716 hasConcept C190283241 @default.
• W2016397716 hasConcept C202751555 @default.
• W2016397716 hasConcept C2780114586 @default.
• W2016397716 hasConcept C29537977 @default.
• W2016397716 hasConcept C502942594 @default.
• W2016397716 hasConcept C54355233 @default.
• W2016397716 hasConcept C54757728 @default.
• W2016397716 hasConcept C55493867 @default.
• W2016397716 hasConcept C81885089 @default.
• W2016397716 hasConcept C86803240 @default.
• W2016397716 hasConcept C95444343 @default.
• W2016397716 hasConceptScore W2016397716C105696609 @default.
• W2016397716 hasConceptScore W2016397716C109316439 @default.
• W2016397716 hasConceptScore W2016397716C153911025 @default.
• W2016397716 hasConceptScore W2016397716C190062978 @default.
• W2016397716 hasConceptScore W2016397716C190283241 @default.
• W2016397716 hasConceptScore W2016397716C202751555 @default.
• W2016397716 hasConceptScore W2016397716C2780114586 @default.
• W2016397716 hasConceptScore W2016397716C29537977 @default.
• W2016397716 hasConceptScore W2016397716C502942594 @default.
• W2016397716 hasConceptScore W2016397716C54355233 @default.
• W2016397716 hasConceptScore W2016397716C54757728 @default.
• W2016397716 hasConceptScore W2016397716C55493867 @default.
• W2016397716 hasConceptScore W2016397716C81885089 @default.
• W2016397716 hasConceptScore W2016397716C86803240 @default.
• W2016397716 hasConceptScore W2016397716C95444343 @default.
• W2016397716 hasLocation W20163977161 @default.
• W2016397716 hasOpenAccess W2016397716 @default.
• W2016397716 hasPrimaryLocation W20163977161 @default.
• W2016397716 hasRelatedWork W1973992251 @default.
• W2016397716 hasRelatedWork W1991050081 @default.
• W2016397716 hasRelatedWork W2007077778 @default.
• W2016397716 hasRelatedWork W2069782995 @default.
• W2016397716 hasRelatedWork W2081519171 @default.
• W2016397716 hasRelatedWork W2086833344 @default.
• W2016397716 hasRelatedWork W2088427566 @default.
• W2016397716 hasRelatedWork W2092963476 @default.
• W2016397716 hasRelatedWork W2318012914 @default.
• W2016397716 hasRelatedWork W2334471177 @default.
• W2016397716 hasRelatedWork W2435730261 @default.
• W2016397716 hasRelatedWork W2559388018 @default.
• W2016397716 hasRelatedWork W2564056866 @default.
• W2016397716 hasRelatedWork W2566332521 @default.
• W2016397716 hasRelatedWork W2586472325 @default.
• W2016397716 hasRelatedWork W2594504601 @default.
• W2016397716 hasRelatedWork W2805695575 @default.
• W2016397716 hasRelatedWork W2979663888 @default.
• W2016397716 hasRelatedWork W2980984880 @default.
• W2016397716 hasRelatedWork W3209881456 @default.
• W2016397716 isParatext "false" @default.
• W2016397716 isRetracted "false" @default.
• W2016397716 magId "2016397716" @default.
• W2016397716 workType "article" @default.